Actinium to Present at the Canaccord Genuity 34th Annual Growth Conference
on August 13th
CEO to Provide Corporate Update on Late- and Mid-Stage Programs Focused on
Acute Myeloid Leukemia and Other Advanced Cancers
Canaccord Growth Conference 2014
NEW YORK -- August 5, 2014
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”),
a biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, today announced that
Dr. Kaushik J. Dave, President and CEO of Actinium, will present at the
Canaccord Genuity 34^th Annual Growth Conference on Wednesday, August 13,
2014, at 9:30 a.m. ET in Boston, MA.
The Company’s presentation is scheduled to begin at 9:30 a.m. ET and will be
available via a live webcast. To access the live audio webcast, please log on
through a link located in the Investors section of Actinium’s website at
www.actiniumpharma.com under the Corporate Presentations tab. A replay will be
available on the Actinium website within 48 hours and will be archived for a
Dr. Dave and other members of the management team will be available for
one-on-one meetings at the conference. Members of the investment community who
are interested in meeting with management should contact their Canaccord
Genuity representative, or Evan Smith, CFA of Actinium Pharmaceuticals, at
646-840-5442 or email@example.com.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based
biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted
radiotherapy is based on its proprietary delivery platform for the therapeutic
utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta
emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients
for hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. The Company is preparing a single, pivotal, multicenter Phase 3
clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia
(AML) patients over the age of 55 with a primary endpoint of durable complete
remission. The Company’s second program, Actimab-A, is continuing its clinical
development in a Phase 1/2 trial for newly diagnosed AML patients over the age
of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based
on management’s current expectations and involve risks and uncertainties,
which may cause actual results to differ materially from those set forth in
the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
Actinium Pharmaceuticals, Inc.
Evan Smith, CFA, +1-646-840-5442
VP Investor Relations and Finance
Press spacebar to pause and continue. Press esc to stop.